Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 9/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3136496 | 0.89 | MAP3K5 (0.45) | MAP3K5LRRK2APPPIK3CAPIK3CG | |
| SCHEMBL3150092 | 0.86 | PIK3CA (0.52) | MAP3K5MAPK13BRAFKDRMAPK12 | |
| SCHEMBL3150363 | 0.83 | MAP3K5 (0.44) | MAP3K5KDRAPPPIK3CAPIK3CG | |
| SCHEMBL24305376 | 0.82 | LRRK2 (0.55) | LRRK2KDR | |
| SCHEMBL3137910 | 0.82 | MAP3K5 (0.44) | MAP3K5LRRK2PIK3CAPIK3CG | |
| SCHEMBL14247285 | 0.81 | MAP3K5 (0.61) | MAP3K5LRRK2MAPK13BRAFKDR | |
| SCHEMBL913680 | 0.79 | PTGS1 (0.58) | — | |
| SCHEMBL6312547 | 0.79 | MAP3K5 (0.46) | MAP3K5 | |
| SCHEMBL3145763 | 0.79 | MAP3K5 (0.40) | MAP3K5LRRK2APPPIK3CAPIK3CG | |
| SCHEMBL3486104 | 0.79 | MAP3K5 (0.66) | MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| EP-1989201-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007095588-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | PIK3CA, PIK3CD, PIK3CB | MAP3K5 192/4885LRRK2 903/4885MAPK13 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.